IL138033A0 - Method of preventing the death of retinal neurons and treating ocular diseases - Google Patents

Method of preventing the death of retinal neurons and treating ocular diseases

Info

Publication number
IL138033A0
IL138033A0 IL13803399A IL13803399A IL138033A0 IL 138033 A0 IL138033 A0 IL 138033A0 IL 13803399 A IL13803399 A IL 13803399A IL 13803399 A IL13803399 A IL 13803399A IL 138033 A0 IL138033 A0 IL 138033A0
Authority
IL
Israel
Prior art keywords
retinal
retinopathies
cells
retinopathy
pigmentosa
Prior art date
Application number
IL13803399A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/240,952 external-priority patent/US6331523B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL138033A0 publication Critical patent/IL138033A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL13803399A 1998-03-12 1999-03-10 Method of preventing the death of retinal neurons and treating ocular diseases IL138033A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4138398A 1998-03-12 1998-03-12
US09/240,952 US6331523B1 (en) 1998-03-12 1999-01-29 Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
PCT/US1999/005375 WO1999045952A2 (en) 1998-03-12 1999-03-10 Method of preventing the death of retinal neurons and treating ocular diseases

Publications (1)

Publication Number Publication Date
IL138033A0 true IL138033A0 (en) 2001-10-31

Family

ID=26718088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13803399A IL138033A0 (en) 1998-03-12 1999-03-10 Method of preventing the death of retinal neurons and treating ocular diseases

Country Status (9)

Country Link
EP (1) EP1061943B1 (xx)
JP (2) JP3764047B2 (xx)
AT (1) ATE226444T1 (xx)
AU (1) AU754380B2 (xx)
CA (1) CA2322380C (xx)
DE (1) DE69903612T2 (xx)
ES (1) ES2186340T3 (xx)
IL (1) IL138033A0 (xx)
WO (1) WO1999045952A2 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2384696A1 (en) * 1999-10-02 2001-04-12 The Government Of The United States Of America Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen
JP4564920B2 (ja) * 2003-04-18 2010-10-20 株式会社最先端医学研究所 眼に適用する疾患治療剤
JP2008064459A (ja) * 2004-12-24 2008-03-21 Univ Kurume 色素上皮由来因子の定量法
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PE20141432A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
JP6628252B2 (ja) * 2014-02-28 2020-01-08 国立大学法人京都大学 虚血性眼疾患の処置用の医薬組成物
SG10201810150UA (en) 2014-03-17 2018-12-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
CN107405507B (zh) 2015-03-02 2022-05-03 阿德夫拉姆生物技术股份有限公司 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6284194A (en) * 1993-03-12 1994-09-26 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)
AU702323B2 (en) * 1994-03-15 1999-02-18 Selective Genetics, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
DK1632574T3 (da) * 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer

Also Published As

Publication number Publication date
ATE226444T1 (de) 2002-11-15
EP1061943B1 (en) 2002-10-23
JP2002526381A (ja) 2002-08-20
AU754380B2 (en) 2002-11-14
JP2006089489A (ja) 2006-04-06
WO1999045952A2 (en) 1999-09-16
CA2322380A1 (en) 1999-09-16
CA2322380C (en) 2008-10-14
JP3764047B2 (ja) 2006-04-05
WO1999045952A3 (en) 2000-11-23
EP1061943A1 (en) 2000-12-27
DE69903612T2 (de) 2003-07-10
DE69903612D1 (de) 2002-11-28
ES2186340T3 (es) 2003-05-01
AU3081399A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
WO2001009327A3 (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
IL138033A0 (en) Method of preventing the death of retinal neurons and treating ocular diseases
NO982275D0 (no) FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
Fraser Neuronal spread of scrapie agent and targeting of lesions within the retino-tectal pathway
Tsutsumi-Miyahara et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation
Dufier et al. Ocular changes in long-term evolution of infantile cystinosis
He et al. Gene expression signatures in tree shrew choroid in response to three myopiagenic conditions
JP2004262947A (ja) 網膜の色素沈着された上皮由来の神経栄養性因子
WO2000053760A3 (en) Method of preventing the death of retinal neurons and treating ocular diseases
Tandon et al. Amniotic membrane grafting for conjunctival and lid surface disease in the acute phase of toxic epidermal necrolysis
Abe et al. Lens epithelial changes and mutated gene expression in patients with myotonic dystrophy
US5629284A (en) Method for treating retinal diseases
ITRM20100100A1 (it) Composizione farmaceutica a base di glicirrizina e polimero eg56 per la preparazione di prodotti ad azione flogolitica.
WO2002089857A3 (en) Trans-viral vector mediated gene transfer to the retina
Shapiro et al. Lipid keratopathy following corneal hydrops
EP0083261B1 (fr) Composition thérapeutique, à base d'inosine monophosphaté, pour le traitement des troubles d'accommodation de l'oeil
LIMAYE et al. Optic disc hamartoma associated with retinitis pigmentosa
Møller et al. Early treatment of granular dystrophy (Groenouw type I)
Travers et al. A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis
Sambhav et al. Necrotizing scleritis in a case of Vogt-Koyanagi-Harada disease
Tabatabaei et al. Clinical risk factors for age-related macular degeneration: A case–control study
Soubrane et al. Laser Treatment of Occult Subretinal New Vessels in Age-Related Macular Degeneration: Feasability study and comparison with natural history
Srinivas et al. Haridra (curcuma longa) and its effect on abhisayanda (conjunctivitis)
Rotman et al. Two asymptomatic plaques on the chest of a young woman
Meffert et al. Laser photocoagulation prophylaxis for CMV retinal detachments

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed